Drug intelligence / Profile preview

cu-yu granules

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Cu-Yu granules is a Traditional Chinese Medicine (TCM) formulation developed by Longhua Hospital, Shanghai University of Traditional Chinese Medicine, specifically for the postoperative management of anal fistula. The drug is designed to promote wound healing, prevent excessive scarring, and protect anal function following surgical intervention. Its therapeutic rationale is based on the TCM principle of "removing stasis" (Qu Yu), which involves improving local blood circulation and reducing inflammation at the wound site. It is currently being evaluated in clinical trials to assess its efficacy in accelerating recovery and improving functional outcomes for patients.

Other names: Cuyu granulesQuyu granules祛瘀颗粒

Beyond the preview

Go deeper on cu-yu granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cu-yu granules.

Explore the full profile